Skip to main content

Table 2 Short-term Results: Primary and Secondary Outcomes

From: Mobile health, exercise and metabolic risk: a randomized controlled trial

  Intervention (n = 67) Active Control (n = 60) Difference in Mean Change at 12-weeks*
Outcome measure Baseline Mean (SD) 12-weeks Mean (SD) Baseline Mean (SD) 12-weeks Mean (SD) Estimate (95% CI) p
SBPrest, mmHg 141.2 (19.7) 138.2 (17.8) 141.4 (18.2) 132.7 (18.4) -5.68 (-10.86 to -0.50) 0.03
DBPrest, mmHg 86.5 (11.0) 84.0 (10.7) 85.8 (9.3) 80.9 (9.0) -2.55 (-5.24 to 0.13) 0.06
WC, cm 105.5 (12.8) 103.3 (12.3) 102.3 (16.6) 100.0 (16.4) -0.36 (-2.18 to 1.46) 0.69
FG, mmol/L 5.29 (1.11) 5.33 (1.03) 4.87 (0.50) 4.94 (0.51) -0.06 (-0.24 to 0.11) 0.47
HbA1c, % 5.86 (0.75) 5.80 (0.68) 5.77 (0.33) 5.75 (0.36) 0.02 (-0.07 to 0.10) 0.65
HbA1c, (mmol/mol) 41 (8.2) 40 (7.4) 40 (3.6) 39 (3.9) 0.2 (-0.8 to 1.1) 0.65
HOMA-IR 2.56 (1.88) 2.38 (1.59) 1.69 (1.15) 1.92 (1.44) 0.12 (-0.30 to 0.53) 0.58
HDL, mmol/L 1.40 (0.39) 1.39 (0.40) 1.45 (0.38) 1.47 (0.38) 0.04 (-0.03 to 0.10) 0.26
LDL, mmol/L 3.14 (0.84) 3.09 (0.96) 3.24 (0.78) 3.09 (0.87) -0.08 (-0.31 to 0.15) 0.51
T-Chol, mmol/L 5.31 (1.01) 5.19 (1.09) 5.37 (0.94) 5.20 (0.98) -0.05 (-0.30 to 0.21) 0.72
TG, mmol/L 1.68 (1.45) 1.52 (0.87) 1.50 (0.70) 1.39 (0.66) -0.04 (-0.20 to 0.13) 0.67
CRPhs, mg/L 3.46 (4.59) 3.34 (3.61) 2.46 (2.64) 2.41 (3.42) -0.16 (-0.84 to 0.53) 0.65
  1. Abbreviations: CI Confidence interval, SBP rest resting systolic blood pressure, DBP rest resting diastolic blood pressure, WC waist circumference, FG fasting glucose, HbA 1c glycated hemoglobin, HOMA-IR Homeostasis Model for Insulin Resistance, HDL high density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, T-Chol total cholesterol, TG triglycerides, CRP hs high sensitivity C-reactive protein.
  2. *Group differences calculated as Active Control – Intervention and adjusted for baseline.
  3. n =59 in the active control group.
  4. n =65 in the intervention group.